Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Significance of Palifermin (Kepivance) in Reduction of Oral Mucositis (OM) Incidence and Acute Graft Versus Host Disease (aGvHD) in Patients with Hematological Diseases Undergoing HSCT.

Blood (2006) 108 (11): 2965.

https://doi.org/10.1182/blood.V108.11.2965.2965

Published: 2006

Journal Articles

Significant Correlation between Survival Endpoints and Exposure to Ofatumumab (HuMax-CD20) in Chronic Lymphocytic Leukemia.

Bertrand Coiffier, H. Tilly, L.M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Wooldridge, J.S. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M. Flensburg, J. Petersen, T. Robak

Blood (2006) 108 (11): 2842.

https://doi.org/10.1182/blood.V108.11.2842.2842

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.

Neil Shah, R. Pasquini, P. Rousselot, S. Jootar, J. Holowiecki, A. Countouriotis, D. Dejardin, T. Hughes, Brian J. Druker

Blood (2006) 108 (11): 167.

https://doi.org/10.1182/blood.V108.11.167.167

Published: 2006

Journal Articles

Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients.

E. Kalinka, PhD, J. Wajs, PhD, K.S. Sulek, M. Blasinska-Morawiec, PhD, P. Centkowski, MD, B. Ceglarek, PhD, T. Robak, J. Holowiecki, G. Mazur, MD, I. Federowicz, PhD, W. Jedrzejczak, M. Watek, MD, K. Warzocha

Blood (2006) 108 (11): 2481.

https://doi.org/10.1182/blood.V108.11.2481.2481

Published: 2006

Journal Articles

Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.

O. Cornely, MD, PhD, J. Maertens, MD, D. Winston, MD, J. Perfect, MD, D. Helfgott, MD, A. Ullmann, MD, J. Holowiecki, MD, D. Stockelberg, MD, Y.-T. Goh, MD, M. Petrini, MD, T. Walsh, MD, J. Gogate, PhD, C. Hardalo, MD, D. Angulo-Gonzalez, MD

Blood (2005) 106 (11): 1844.

https://doi.org/10.1182/blood.V106.11.1844.1844

Published: 2005

Journal Articles

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

Bertrand Coiffier, H. Tilly, L. M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. J. Walewski, M.F. Flensburg, J. Petersen, T. Robak

Blood (2005) 106 (11): 448.

https://doi.org/10.1182/blood.V106.11.448.448

Published: 2005

Journal Articles

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma

A Osterborg, MA Boogaerts, R Cimino, U Essers, J Holowiecki, G Juliusson, G Jager, A Najman, D Peest

Blood (1996) 87 (7): 2675–2682.

https://doi.org/10.1182/blood.V87.7.2675.bloodjournal8772675

Published: 1996

NARROW

The Significance of Palifermin (Kepivance) in Reduction of Oral Mucositis (OM) Incidence and Acute Graft Versus Host Disease (aGvHD) in Patients with Hematological Diseases Undergoing HSCT.

Significant Correlation between Survival Endpoints and Exposure to Ofatumumab (HuMax-CD20) in Chronic Lymphocytic Leukemia.

Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.

Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients.

Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

The Significance of Palifermin (Kepivance) in Reduction of Oral Mucositis (OM) Incidence and Acute Graft Versus Host Disease (aGvHD) in Patients with Hematological Diseases Undergoing HSCT.

Significant Correlation between Survival Endpoints and Exposure to Ofatumumab (HuMax-CD20) in Chronic Lymphocytic Leukemia.

Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.

Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients.

Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.

HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial.

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only